COMP <GO>
ELV vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Elevance Health Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ELV 6
— MRK 8
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: MRK
LAST: $420.07 (-0.46%) • MKT CAP: $91.18B
options-implied-move
7.10%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
6.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELV VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELV | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.40% | 74.80% | +14.60 | ELV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | 20.70% | -12.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.8x | 15.3x | -1.50 | ELV | /valuation <GO> |
| Free Cash Flow Yield | 3.48% | 3.42% | +0.06 | ELV | /fcf-yield <GO> |
| Operating Margin | 3.60% | 34.30% | -30.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 2.80% | 28.10% | -25.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 12.50% | 1.30% | +11.20 | ELV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.68% | 2.26% | -0.58 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.17 | 5.19 | -2.02 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.8 | 56.9 | -6.09 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.92 | +0.15 | ELV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 13.5x | 18.4x | -4.90 | ELV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $91.18B | $361.02B | -$269.84B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELV REV | MRK REV | ELV GROSS % | MRK GROSS % | ELV FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $199.13B | $65.01B | 89.4% | 74.8% | $3.17B | $12.36B |
| FY 2024 | $177.01B | $64.17B | 88.8% | 76.3% | $4.55B | $18.10B |
| FY 2023 | $171.34B | $60.12B | 44.0% | 44.0% | $350.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELV // BETA 1.07
MRK // BETA 0.92